top of page
News & Events
BrainsWay Reports Third Quarter 2021 Financial Results and Operational Highlights
Revenue Growth of 34% Year-over-Year in Q3 2021 Received Regulatory Clearance for Deep TMS™ System for Treatment of Anxious Depression...
Nov 17, 2021
BrainsWay to Report Third Quarter 2021 Financial Results on November 17, 2021
BURLINGTON, Mass. and JERUSALEM, Nov. 03, 2021 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a...
Nov 3, 2021
COVID-19 has accelerated the mental health crisis
The importance of mental health is highlighted, with statements from BrainsWay and Chief Medical Officer Dr. Aron Tendler calling for...
Oct 26, 2021
BrainsWay Announces Prominent Addition to Scientific Advisory Board
Zafiris Daskalakis, MD, PhD to Bring Extensive Research and Clinical Expertise to Assist in Guiding Growth and Clinical Impact Strategy...
Oct 12, 2021
BrainsWay Announces Data Published in World Psychiatry on Deep Transcranial Magnetic Stimulation (De
BrainsWay Announces Data Published in World Psychiatry on Deep Transcranial Magnetic Stimulation (Deep TMS™) for Smoking Addiction...
Sep 30, 2021
Mental Health Recap: 4 Must-Read Studies From August 2021
Highlighting the recent FDA clearance for anxious depression with references to the study and a quote from BrainsWay Chief Medical...
Sep 20, 2021
MUSC Health among first to offer brain stimulation to try to help smokers quit
Patient testimonials, smoker statistics, and discussion around BrainsWay’s Deep TMS smoking addiction treatment process and experiences....
Sep 20, 2021
BrainsWay to Participate in Two Upcoming Investor Conferences in 2021
BURLINGTON, Mass. and JERUSALEM, Sept. 09, 2021 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a...
Sep 9, 2021
BrainsWay featured on CBS News
Dr. Tendler discusses how emerging technologies, such as BrainsWay’s Deep TMS™, offer hope to those suffering from severe symptoms of...
Sep 9, 2021
Setting Your Company Up for Success When Navigating Coverage Conversations
BrainsWay CEO and President, Christopher von Jako, PhD discusses the navigation, education, and partner selection process for the...
Sep 7, 2021
BrainsWay to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BURLINGTON, Mass. and JERUSALEM, August 30, 2021 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Aug 30, 2021
Transcranial Magnetic Stimulation Device Cleared for Anxious Depression
Summary of the release and research lending to the FDA-clearance of anxious depression, with quotes from Dr. Aron Tendler on how this...
Aug 25, 2021
BrainsWay receives FDA clearance for noninvasive comorbid anxiety, depression treatment
Summary of the release, highlighting how this FDA clearance will allow BrainsWay to increase patient pool to include patients who have...
Aug 20, 2021
FDA Clears Deep TMS System for Comorbid Anxiety Symptoms
Highlighting the FDA clearance announcement as a promising step in managing comorbid anxiety symptoms, offering hope to a myriad of...
Aug 19, 2021
FDA clearance for Deep TMS system in decreasing anxiety symptoms
FDA Clearance for Deep TMS system in decreasing anxiety symptoms in depressed patients, as well as highlights of all other FDA cleared...
Aug 19, 2021
BrainsWay clinches FDA nod for magnetic stimulation device to ease anxious depression
In-depth explanation as to how Deep TMS’s newest anxiety-depression clearance will help achieve BrainsWay’s ultimate goal of serving a...
Aug 18, 2021
FDA OKs Stimulation Device for Anxiety in Depression
Coverage of BrainsWay receiving FDA Clearance for the treatment of comorbid anxiety symptoms in adults patients with depression, as well...
Aug 18, 2021
FDA Clears BrainsWay Deep TMS™ System for Decreasing Anxiety Symptoms in Depressed Patients
Expanded Depression Indication Further Demonstrates Company’s Leadership Position BURLINGTON, Mass. and JERUSALEM, Aug. 18, 2021 (GLOBE...
Aug 18, 2021
bottom of page